title: Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
abstract: In our earlier study we reported the antidepressant activity of ondansetron in obese mice. The present study investigates the effect of ondansetron on depression and anxiety associated with obesity in experimental mice with biochemical evidences. Male Swiss albino mice were fed with high fat diet (HFD) for 14weeks to induce obesity. Then the subsequent treatment with ondansetron (0.5 and 1mg/kg, p.o.), classical antidepressant escitalopram (ESC) (10mg/kg, p.o.) and vehicle (distilled water 10ml/kg, p.o.) was given once daily for 28days. Behavioral assay for depression including sucrose preference test, forced swim test (FST) and anxiety such as light dark test (LDT) and hole board test (HBT) were performed in obese mice. Furthermore, in biochemical estimations oral glucose tolerance test (OGTT), plasma leptin, insulin, corticosterone, brain oxidative stress marker malonaldehyde (MDA), antioxidant reduced glutathione (GSH) and serotonin assays were performed. Results indicated that HFD fed obese mice showed severe depressive and anxiety-like behaviors. Chronic treatment with ondansetron inhibited the co-morbid depression and anxiety in obese mice by increasing sucrose consumption in sucrose preference test and reducing the immobility time in FST, increasing time and transitions of light chamber in LDT, improving head dip and crossing scores in HBT compared to HFD control mice. Ondansetron in obese mice inhibited glucose sensitivity in OGTT, improved plasma leptin and insulin sensitivity, reversed hypothalamic pituitary adrenal (HPA) axis hyperactivity by reducing the corticosterone concentration, restored brain pro-oxidant/anti-oxidant balance by inhibiting MDA and elevating GSH concentrations and facilitated serotonergic neurotransmission. In conclusion, ondansetron reversed the co-morbid depression and anxiety associated with obesity in experimental mice by attenuating the behavioral and biochemical abnormalities.
authors.affiliation: Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Rajasthan 333031, India. Electronic address: yashkurhe@gmail.com.
authors.forename: Yeshwant
authors.initials: Y
authors.lastname: Kurhe
authors.affiliation: Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Rajasthan 333031, India.
authors.forename: Radhakrishnan
authors.initials: R
authors.lastname: Mahesh
mesh_terms: D000818:Animals; D001007:Anxiety / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D001522:Behavior, Animal / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D015283:Citalopram / Q000494:pharmacology; D003345:Corticosterone / Q000097:blood; D003863:Depression / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D059305:Diet, High-Fat; D005951:Glucose Tolerance Test; D005978:Glutathione / Q000378:metabolism; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D008820:Mice, Obese; D009765:Obesity / Q000150:complications* / Q000378:metabolism; D017294:Ondansetron / Q000494:pharmacology* / Q000627:therapeutic use; D018384:Oxidative Stress / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism*; D009435:Synaptic Transmission / Q000187:drug effects*
chemical_list: D007328:Insulin; D020738:Leptin; D015283:Citalopram; D012701:Serotonin; D017294:Ondansetron; D008315:Malondialdehyde; D005978:Glutathione; D003345:Corticosterone
keywords: Anxiety leptin; Depression; HPA axis; Insulin; Oxidative stress; Serotonin